International Clinical Trial: Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215637) titled 'Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Chong Kun Dang Pharmaceutical

Condition: Advanced Solid Tumors Metastatic Solid Tumors

Intervention: Drug: CKD-512

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 2025

Target Sample Size: 60

Countries of Recruitment: South Korea

To know more, visi...